Corcept Therapeutics Inc (NASDAQ:CORT) Institutional Investors Q1 2018 Sentiment

July 12, 2018 - By Tina Thibodeau

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo

Sentiment for Corcept Therapeutics Inc (NASDAQ:CORT)

Corcept Therapeutics Inc (NASDAQ:CORT) institutional sentiment decreased to 1.28 in 2018 Q1. Its down -0.21, from 1.49 in 2017Q4. The ratio has worsened, as 106 funds increased and opened new positions, while 83 sold and decreased their equity positions in Corcept Therapeutics Inc. The funds in our partner’s database now possess: 84.82 million shares, down from 87.40 million shares in 2017Q4. Also, the number of funds holding Corcept Therapeutics Inc in their top 10 positions decreased from 5 to 4 for a decrease of 1. Sold All: 28 Reduced: 55 Increased: 60 New Position: 46.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.75 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 13.45 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

The stock decreased 1.49% or $0.23 during the last trading session, reaching $15.2. About 385,521 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since July 12, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on August, 7. They expect $0.16 earnings per share, up 60.00 % or $0.06 from last year’s $0.1 per share. CORT’s profit will be $18.44 million for 23.75 P/E if the $0.16 EPS becomes a reality. After $0.14 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 14.29 % EPS growth.

Consonance Capital Management Lp holds 7.8% of its portfolio in Corcept Therapeutics Incorporated for 5.19 million shares. Tanaka Capital Management Inc owns 144,602 shares or 5.69% of their US portfolio. Moreover, Ingalls & Snyder Llc has 5.47% invested in the company for 6.82 million shares. The California-based Fort Point Capital Partners Llc has invested 5.07% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 245,279 shares.

Since January 1, 0001, it had 1 insider buy, and 7 sales for $1.12 million activity.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Ratings analysis reveals 75% of Corcept Therapeutics Inc’s analysts are positive. Out of 4 Wall Street analysts rating Corcept Therapeutics Inc, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3000 while the high is $3200. The stock’s average target of $30.67 is 101.78% above today’s ($15.2) share price. CORT was included in 7 notes of analysts from March 8, 2018. FBR Capital maintained the stock with “Buy” rating in Tuesday, March 20 report. The firm earned “Hold” rating on Thursday, May 31 by Stifel Nicolaus. The company was maintained on Tuesday, June 12 by FBR Capital. As per Friday, April 13, the company rating was initiated by Seaport Global. FBR Capital maintained the stock with “Buy” rating in Tuesday, June 19 report. The stock has “Buy” rating by FBR Capital on Thursday, March 8.

Another recent and important Corcept Therapeutics Incorporated (NASDAQ:CORT) news was published by which published an article titled: “Analysis: Positioning to Benefit within QEP Resources, Corcept Therapeutics, Buckle, Noble Energy, Windstream, and …” on June 29, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: